BRD2 and systemic lupus erythematosus: A study on SLE patients with teriflunomide (pyrimidine synthesis - inhibitor drug class–one of the NAT substrate) therapy, showed the SNP did not fulfill the relative standard error, representing the uncertainty of the effect (RSE <47%) (Lam, 2018; Yao et al., 2019b) (Table S1).